Related Experiment Video
Updated: Aug 22, 2026

Detection of Low Copy Number Integrated Viral DNA Formed by In Vitro Hepatitis B Infection
Published on: November 7, 2018
Hepatitis C virus in the setting of HIV or hepatitis B virus coinfection
Richard K Sterling1, Mark S Sulkowski
1Virginia Commonwealth University Health System/Medical College of Virginia, Richmond, Virginia 23298, USA. rksterli@hsc.vcu.edu
Insights
Coinfection with hepatitis C virus (HCV) or hepatitis B virus (HBV) is common in HIV patients. Managing HCV/HBV coinfection in HIV requires specific treatment strategies to prevent severe liver disease and hepatocellular carcinoma.
Area of Science:
- Hepatology
- Infectious Diseases
- Virology
Background:
- Coinfection with hepatitis C virus (HCV) or hepatitis B virus (HBV) is prevalent in HIV-infected individuals due to shared transmission routes.
- Improved life expectancy in HIV patients due to antiretroviral therapy has made HCV-related liver disease a significant comorbidity.
- HIV coinfection can exacerbate HCV progression, leading to increased liver disease severity, fibrosis, and hepatocellular carcinoma (HCC) risk.
Purpose of the Study:
- To summarize the impact of HCV and HBV coinfection on HIV-infected individuals.
- To review current treatment recommendations for chronic HCV in HIV-coinfected patients.
- To discuss the undefined optimal treatment for chronic HCV in patients coinfected with HBV.
Main Methods:
- Literature review of studies on HIV, HCV, and HBV coinfection.
- Analysis of current clinical guidelines for managing coinfections.
- Synthesis of data on disease progression and treatment outcomes.
Main Results:
- HIV coinfection is associated with higher HCV RNA levels and accelerated liver fibrosis.
- Coinfection with HCV and HBV can lead to more severe liver disease and a greater risk of HCC compared to HCV alone.
- Pegylated interferon alfa plus ribavirin is recommended for treating chronic HCV in eligible HIV-infected persons.
Conclusions:
- HCV and HBV coinfection significantly impacts liver disease progression in HIV patients.
- Treatment for chronic HCV in HIV-coinfected individuals is guided by current recommendations.
- Optimal treatment strategies for chronic HCV in patients coinfected with HBV require further definition, potentially including interferon-based therapies and additional antivirals.
Abstract:
Because of shared routes of transmission, coinfection with hepatitis C virus (HCV) or hepatitis B virus (HBV), or both, is common among HIV-infected persons, affecting approximately 15 to 30% and 10 to 15% of patients, respectively. Advances in antiretroviral therapy have improved the life expectancy of patients infected with HIV, and, as a consequence, HCV-related liver disease has emerged as a significant comorbid disease among such patients. Concurrent HIV infection may be associated with higher serum HCV RNA levels, accelerated progression of hepatic fibrosis, increased risk of end-stage liver disease, hepatocellular carcinoma and death among persons coinfected with hepatitis C. Similarly, coinfection with HCV and HBV may lead to more severe liver disease and greater risk of hepatocellular carcinoma (HCC) than does HCV infection alone. Although definitive randomized controlled trials are not yet completed, current guidelines recommend the use of pegylated interferon alfa plus ribavirin for the treatment of chronic HCV in eligible HIV-infected persons. Conversely, the optimal treatment of chronic HCV in persons with chronic HBV infection has not been defined but may include pegylated interferon alfa plus ribavirin, with or without additional antiviral agents, such as lamivudine or adefovir, or both.
Related Concept Videos
Hepatitis
Viral Hepatitis I: Introduction
Viruses with RNA Genomes
Retrovirus Life Cycles
Inhibitors of Virion Maturation and Assembly
Retroviruses
